VISEN PHARMA-B Shares Surge Over 15% Following New Partnership on Healthcare Payment Models

Stock News07-02

Shares of VISEN PHARMA-B (02561) experienced a significant rise of more than 15% during the morning trading session. At the time of writing, the stock was up 15.22%, trading at HK$23.02 with a turnover of HK$1.482 million.

The notable increase follows the company's recent announcement of a project collaboration with Magical Health, a leading diversified healthcare payment platform in China. The partnership aims to leverage the respective strengths of both parties in the fields of innovative therapies and health services.

Focus of the Collaboration

Together, they will explore multiple pathways to enhance the accessibility and affordability of innovative treatments for endocrine diseases. The ultimate goal is to help patients in China more conveniently benefit from cutting-edge global therapeutic solutions.

Executive Commentary

Chen Jun, Chief Commercial Officer of VISEN PHARMA-B, commented on the strategic move. He stated that the company has consistently focused on introducing "first-in-class" or "best-in-class" innovative therapies to the Chinese market. The mission extends beyond making treatments available to ensuring patients have access to high-quality medicines.

He highlighted that VISEN possesses globally advanced endocrine innovation therapies, while Magical Health brings extensive practical experience in diversified payment solutions. This collaboration is expected to accelerate the process of making their innovative products accessible to a wider patient population, effectively bridging the gap from "having medicine available" to "being able to afford the medicine."

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1174931985?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-07-02 10:34","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1174931985","market":"sh","top_or_hot":-1,"title":"VISEN PHARMA-B Shares Surge Over 15% Following New Partnership on Healthcare Payment Models","media":"Stock News","content":"<p>Shares of <b>VISEN PHARMA-B</b> (<b>02561</b>) experienced a significant rise of more than 15% during the morning trading session. At the time of writing, the stock was up 15.22%, trading at HK$23.02 with a turnover of HK$1.482 million.<br><br>\nThe notable increase follows the company's recent announcement of a project collaboration with Magical Health, a leading diversified healthcare payment platform in China. The partnership aims to leverage the respective strengths of both parties in the fields of innovative therapies and health services.<br><br>\n<b>Focus of the Collaboration</b><br><br>\nTogether, they will explore multiple pathways to enhance the accessibility and affordability of innovative treatments for endocrine diseases. The ultimate goal is to help patients in China more conveniently benefit from cutting-edge global therapeutic solutions.<br><br>\n<b>Executive Commentary</b><br><br>\nChen Jun, Chief Commercial Officer of VISEN PHARMA-B, commented on the strategic move. He stated that the company has consistently focused on introducing \"first-in-class\" or \"best-in-class\" innovative therapies to the Chinese market. The mission extends beyond making treatments available to ensuring patients have access to high-quality medicines.<br><br>\nHe highlighted that VISEN possesses globally advanced endocrine innovation therapies, while Magical Health brings extensive practical experience in diversified payment solutions. This collaboration is expected to accelerate the process of making their innovative products accessible to a wider patient population, effectively bridging the gap from \"having medicine available\" to \"being able to afford the medicine.\"<br><br></p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>VISEN PHARMA-B Shares Surge Over 15% Following New Partnership on Healthcare Payment Models</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nVISEN PHARMA-B Shares Surge Over 15% Following New Partnership on Healthcare Payment Models\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036600163\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock News </p>\n<p class=\"h-time\">2026-07-02 10:34</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Shares of <b>VISEN PHARMA-B</b> (<b>02561</b>) experienced a significant rise of more than 15% during the morning trading session. At the time of writing, the stock was up 15.22%, trading at HK$23.02 with a turnover of HK$1.482 million.<br><br>\nThe notable increase follows the company's recent announcement of a project collaboration with Magical Health, a leading diversified healthcare payment platform in China. The partnership aims to leverage the respective strengths of both parties in the fields of innovative therapies and health services.<br><br>\n<b>Focus of the Collaboration</b><br><br>\nTogether, they will explore multiple pathways to enhance the accessibility and affordability of innovative treatments for endocrine diseases. The ultimate goal is to help patients in China more conveniently benefit from cutting-edge global therapeutic solutions.<br><br>\n<b>Executive Commentary</b><br><br>\nChen Jun, Chief Commercial Officer of VISEN PHARMA-B, commented on the strategic move. He stated that the company has consistently focused on introducing \"first-in-class\" or \"best-in-class\" innovative therapies to the Chinese market. The mission extends beyond making treatments available to ensuring patients have access to high-quality medicines.<br><br>\nHe highlighted that VISEN possesses globally advanced endocrine innovation therapies, while Magical Health brings extensive practical experience in diversified payment solutions. This collaboration is expected to accelerate the process of making their innovative products accessible to a wider patient population, effectively bridging the gap from \"having medicine available\" to \"being able to afford the medicine.\"<br><br></p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4588","symbol_name":"碎股","start_time":0,"source_url":"","article_id":"1174931985","we_media_id":"1036600163","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1174931985","pubTimestamp":1782959668,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Stock News","introduction":"Global Stock News First-Time Broadcast","home_visible":1,"id":"1036600163","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"Shares of VISEN PHARMA-B (02561) experienced a significant rise of more than 15% during the morning trading session. At the time of writing, the stock was up 15.22%, trading at HK$23.02 with a...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4588":"碎股","BK4585":"ETF&股票定投概念","BK1161":"生物科技","02561":"维昇药业-B","VXUS":"国际股票ETF-Vanguard"},"translate_title":"VISEN PHARMA-B在医疗支付模式上建立新合作伙伴关系后股价飙升超过15%","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"VXUS":1,"02561":1},"content_text":"Shares of VISEN PHARMA-B (02561) experienced a significant rise of more than 15% during the morning trading session. At the time of writing, the stock was up 15.22%, trading at HK$23.02 with a turnover of HK$1.482 million.\nThe notable increase follows the company's recent announcement of a project collaboration with Magical Health, a leading diversified healthcare payment platform in China. The partnership aims to leverage the respective strengths of both parties in the fields of innovative therapies and health services.\nFocus of the Collaboration\nTogether, they will explore multiple pathways to enhance the accessibility and affordability of innovative treatments for endocrine diseases. The ultimate goal is to help patients in China more conveniently benefit from cutting-edge global therapeutic solutions.\nExecutive Commentary\nChen Jun, Chief Commercial Officer of VISEN PHARMA-B, commented on the strategic move. He stated that the company has consistently focused on introducing \"first-in-class\" or \"best-in-class\" innovative therapies to the Chinese market. The mission extends beyond making treatments available to ensuring patients have access to high-quality medicines.\nHe highlighted that VISEN possesses globally advanced endocrine innovation therapies, while Magical Health brings extensive practical experience in diversified payment solutions. This collaboration is expected to accelerate the process of making their innovative products accessible to a wider patient population, effectively bridging the gap from \"having medicine available\" to \"being able to afford the medicine.\"","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"corporation","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.45.2","shortVersion":"4.45.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1174931985","isCrawlerRequest":true}